Zyclara (imiquimod) / Mochida, Viatris, Bausch Health - LARVOL DELTA

Toll-like receptor 7 (TLR7) agonists and OX40 agonists injection combined with SBRT in advanced tumor patients. (ASCO 2025) - P2 | "We have developed a compound immune adjuvant (RO adjuvant) composed of Toll-Like receptor 7 (TLR7) agonists (imiquimod/R837) and OX40 agonists, combining with SBRT as "R-ISV-RO"... "R-ISV-RO" combined with anti-PD-1 mAb has demonstrated reliable safety as well as encouraging efficacy in both overall and target lesion responses. The study is still ongoing."

Clinical • Metastases • Cardiovascular • Endocrine Disorders • Hematological Disorders • Leukopenia • Oncology • Sarcoma • Solid Tumor

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - P1 | N=117 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CA 19-9

S060 Melanoma in 2026 (AAD 2026) - "From the available worldwide evidence, faculty speakers will address: appropriate biopsy techniques, pathology assessment (including AJCC 8th edition staging), molecular/gene expression profiling (for biopsy, pathologic assessment and prognosis), sentinel lymph node biopsy (including risk prediction tools), surgery (including Mohs micrographic surgery and staged excision with permanent sections), nonsurgical therapy for melanoma in situ/lentigo maligna type (including topical imiquimod and radiotherapy), baseline and surveillance imaging, and adjuvant therapy for resected stage II (primary) and stage III (node-positive) melanoma...3. Describe the role of adjuvant therapy for resected stage II and stage III melanoma, including potential risks and benefits."

Cutaneous Melanoma • Melanoma • Solid Tumor

Primary extramammary paget's disease of the vulva: dermoscopic clues to early, asymptomatic lesions (ESGO 2026) - "All were managed non-surgically with topical imiquimod 5% cream.Results Lesions appeared as sharply demarcated milky-pink plaques on the labia majora, perineum, or mons without ulceration, oozing, or crusting...________________________________________ Conclusion Early vulvar EMPD may manifest as well-defined milky-pink plaques with glomerular vascularity and prominent glandular openings on dermoscopy—distinct from erosive or crusted late lesions. Recognition of these subtle features enables earlier biopsy and safe non-surgical management in selected patients."

Oncology

U045 Field Cancerization Therapies: Medical Dermatology and Beyond (AAD 2026) - "This session will outline the standard of care field therapies including and not limited to topical 5- fluorouracil, imiquimod, conventional/daylight photodynamic therapy, lasers, peels and other modalities. 3. Select the right candidates for field directed therapies and for a variety of cutaneous entities."

Actinic Keratosis • Dermatology • Oncology

Itching for answers: A case of chronic vulvar lesions revealing paget's disease (ESGO 2026) - "Imiquimod was started but discontinued due to pain intolerance...In this case, the successful novel operative approach streamlined intraoperative decision-making. Conclusion Ultimately, clinical suspicion and early diagnosis are key to preventing the progression of EMPD and the operational technique used can serve as a model for future cases."

Clinical • Gynecologic Cancers • Oncology • Solid Tumor • Vulvar Cancer

Anal HPV screening in high-risk patients: the aarau interdisciplinary colposcopy clinic (ESGO 2026) - "Among those treated, laser therapy was most frequently applied (five cases), followed by topical imiquimod (three cases), while one patient underwent surgical excision for PAIN III.Conclusion The Aarau interdisciplinary colposcopy clinic demonstrates that targeted screening and collaborative management of high‑risk patients is effective for the early detection and treatment of anal neoplasia. This model represents a cost‑efficient, single‑unit approach that provides a feasible framework for anal cancer prevention and resource optimisation."

Clinical • Anal Carcinoma • Oncology • Solid Tumor

Topical immunomodulatory treatment (IMIQUIMOD) of cervical intraepithelial lesions:cytological and molecular response rate (ESGO 2026) - "2. According to this data, exclusive cytological controls could be considered as a tool to control the response to the topical treatment."

Immunomodulating • Oncology

Risk factors for vulvar intraepithelial neoplasia recurrence - long term follow-up of a randomised trial for primary imiquimod versus surgery (ESGO 2026) - P3 | "Recurrent vulvar HSIL showed a significantly higher intraepithelial infiltration of CD33+ monocytes compared to non-recurrent lesions (p=0.04), suggesting an immunosuppressive microenvironment. Conclusion Recurrent HSIL are common after surgical or topical vulvar HSIL treatment and occur in 20-30% of patients within 5 years Pre-treatment immune infiltrates seem to be a predictor of long-term recurrence risk."

Clinical • Surgery • Oncology • CD33

Comparison of conservative treatment of cervical intraepithelial lesions with imiquimod with standard excisional technique using LLETZ: A two-year follow up of a randomized controlled trial (ESGO 2026) - P=N/A | "Over 80% of patients with successful primary IMQ treatment did not need further intervention. HPV positivity at two years was 12% in both groups, indicating similar clearance."

Clinical • Oncology

Successful Treatment of Proliferative Verrucous Leukoplakia With Topical Imiquimod: A Case Report and Review of the Literature. (PubMed, J Oral Maxillofac Surg) - "Herein, we report the treatment outcome of a middle-aged female patient who declined surgical intervention and was instead managed solely with topical imiquimod, a Toll-like receptor 7 (TLR7) agonist. To date, no signs of recurrence have occurred."

Journal

PRITELIVIR DEMONSTRATED SUPERIOR EFFICACY COMPARED TO INVESTIGATOR'S CHOICE TREATMENT FOR REFRACTORY HERPES SIMPLEX VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS: PRIOH-1, PHASE 3 SAFETY AND EFFICACY (EBMT 2026) - P3 | " In this randomized (1:1), controlled, open label trial, 101 IC patients (≥16 years) with R±R HSV mucocutaneous infection received oral pritelivir (100 mg daily; 400 mg loading dose) or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod) for up to 28 days, extendable to 42 days. Eligibility criteria included hematopoietic cell transplant, solid organ transplant, HIV, malignancy, or chronic use of immunosuppressive treatment with refractory/clinical failure (defined as no clinical improvement of lesions after ≥7 days of standard of care nucleoside analogue therapy or confirmed acyclovir resistance)... Pritelivir met the Phase 3 primary endpoint, demonstrating statistically superior efficacy compared with ICT, with a favorable safety and tolerability profile. These findings support pritelivir as a promising oral agent to address the unmet needs of refractory HSV infections in IC patients.Table 1 Incidence of TEAEs (≥ 10%): Pritelivir vs...."

Clinical • P3 data • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Primary Immunodeficiency • Solid Organ Transplantation

A bilayered microneedle patch loaded with methotrexate and dexamethasone for transdermal treatment of psoriasis. (PubMed, Sci Rep) - "The patch successfully traversed imiquimod (IMQ)-induced thickened epidermis in murine models to achieve intralesional drug delivery and effectively alleviate psoriasis-like skin inflammation. Versus tacrolimus ointment (positive control), MTX@DXM-MNs markedly alleviated the manifestations of stratum corneum thickening, erythema, and scaling in a mouse model and attenuated the levels of inflammatory mediators in skin tissues and peripheral blood as well as splenic indices. In conclusion, the MTX@DXM-MN bilayered microneedle patch provides a new strategy for the efficient and safe treatment of psoriasis through the temporal and spatial synergistic effects of an outer layer for the immediate release of a hormone and an inner layer for the slow release of an immunosuppressant. Thus, this patch has potential as a future clinical alternative for the treatment of psoriasis."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis

Pritelivir Demonstrated Superior Efficacy Compared to Investigator’s Choice Treatment for Refractory Herpes Simplex Virus Infections In Immunocompromised Patients: PRIOH-1, Phase 3 Safety and Efficacy (TCT-ASTCT-CIBMTR 2026) - "Introduction Pritelivir is a novel oral helicase-primase inhibitor, active against HSV-1 and HSV-2, including strains resistant to nucleoside analogues and foscarnet.ObjectivesPRIOH-1 evaluated the safety and efficacy of pritelivir vs. investigator’s choice therapy (ICT) in immunocompromised (IC) patients with refractory herpes simplex virus (HSV) infection, with or without resistance (R±R).MethodsIn this randomized (1:1), controlled, open label trial, 101 IC patients (≥16 years) with R±R HSV mucocutaneous infection received oral pritelivir (100 mg daily; 400 mg loading dose) or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod) for up to 28 days, extendable to 42 days. Eligibility criteria included hematopoietic cell transplant, solid organ transplant, HIV, malignancy, or chronic use of immunosuppressive treatment with refractory/clinical failure (defined as no clinical improvement of lesions after ≥7 days of standard of care nucleoside analogue..."

Clinical • Late-breaking abstract • P3 data • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Primary Immunodeficiency • Solid Organ Transplantation

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: James Felker | Trial completion date: Dec 2026 ➔ Dec 2025 | Active, not recruiting ➔ Terminated; Closed supratentorial arm prematurely secondary to lack of enrollment

Trial completion date • Trial termination • Ependymoma • Oncology • Solid Tumor

Akkermansia Muciniphila Ameliorates Imiquimod-Induced Skin Thickening, Colitis, and Gut Microbiota Alterations: A Metagenome Association Study. (PubMed, Inflammation) - No abstract available

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology

Evaluation of imiquimod- and LPS-induced skin inflammation models in healthy volunteers (ESCMID Global 2026) - No abstract available

Clinical • Dermatitis • Inflammation

The Impact of Vehicle Occlusivity on Skin Delivery and Activity of a Janus Kinase Inhibitor: Comparison of Oil-Based Formulations. (PubMed, Pharmaceutics) - "Stability, rheology, spreadability, in vitro release, ex vivo permeation, and skin retention were evaluated, along with the safety and efficacy in HET-CAM and imiquimod-induced psoriasis murine models. These results demonstrate that the vehicle occlusivity decisively modulates baricitinib's release and activity. LLV formulation favored drug retention and enhanced permeation at 24 h. Overall, excipient selection is important in designing safe and effective topical JAK inhibitor formulations."

Journal • Dermatology • Immunology • Psoriasis

Lipopolysaccharide and imiquimod stimulation of potential immune biomarkers in whole blood predict alcohol use disorder risk based on AUDIT scores. (PubMed, Alcohol Clin Exp Res (Hoboken)) - "LPS and IMQ stimulations unmasked immune response patterns that separated high- from low-risk individuals, with exaggerated pro-inflammatory responses in the high-risk group. IL-1β, IL-3, IL-18, and CCL11 repeatedly predicted AUDIT scores, with IL-1β and IL-3 LPS-dominant and CCL11 and IL-18 LPS/IMQ stimulus-shared. Stimulation-evoked mediator profiling may complement self-report screening and improve risk stratification in drinkers. Further studies are needed to address the exploratory nature of the results."

Biomarker • IO biomarker • Journal • Addiction (Opioid and Alcohol) • Inflammation • CCL11 • CCL4 • CXCL8 • IL18 • IL1B • IL6 • IL7 • TLR4 • TLR7

Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer. (PubMed, Mater Today Bio) - "To address this, a combination strategy integrating chemotherapy and immunotherapy was employed by co-delivering epirubicin (EPI) and the immune modulator imiquimod (IMQ) using a folate-modified nanocarrier...In an orthotopic BC model, FA-HES-EPI/IMQ micelles significantly enhanced drug accumulation at the tumor site, repolarized M2-type tumor-associated macrophages (TAMs) toward the M1 phenotype, remodeled the tumor stroma, and achieved a tumor inhibition rate of 96.7 %, markedly surpassing that of FA-HES-EPI micelles (86.6 %) and free EPI (62.3 %), with negligible systemic toxicity. This pH-responsive co-delivery system represents a promising approach to improve both efficacy and safety in bladder cancer treatment."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Loss of Galectin-3 in the epidermis exacerbates psoriasis pathogenesis via inhibiting autophagy. (PubMed, Life Sci) - "Gal3 loss exacerbates psoriasis by impairing the autophagic process. These findings position Gal3 as a key protective factor against psoriasis, providing new insights into its role in the pathogenesis of this disease."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • LGALS3 • SIRT1 • SQSTM1

Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab Plus Albumin-Bound Paclitaxel/Carboplatin in the Neoadjuvant Treatment of Early-Stage High-Risk Triple-Negative Breast Cancer (ChiCTR) - P2 | N=45 | Not yet recruiting | Sponsor: The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-1 • PD-L1

Efficacy and Safety of Microneedling Combined with Topical Medications for Psoriatic Nails (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: China-Japan Friendship Hospital; China-Japan Friendship Hospital

New P4 trial • Dermatology • Immunology • Psoriasis

Fc-enhanced anti-CCR6 antibody elicits robust therapeutic effects across multiple autoimmune diseases. (PubMed, Front Immunol) - "In a bleomycin-induced scleroderma model, αhCCR6 mAb treatment markedly reduced dermal thickening and attenuated scleroderma-associated lung inflammation and fibrosis. In the imiquimod-induced psoriasis model, administration of αhCCR6 mAb led to significant reductions in skin thickening, epidermal hyperplasia, and dermal immune cell infiltration...Thus, our findings demonstrated that CCR6-targeted therapy could be a promising and effective approach for the treatment of Th17-mediated inflammatory disorders. Moreover, we believe this approach may overcome the challenge of chemokine receptor redundancy by leveraging receptor-specific signatures to eliminate pathogenic leukocyte subsets with high precision."

Journal • Dermatology • Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Pneumonia • Psoriasis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • CCR6 • IL17A

Cedrol from Platycladus orientalis (L.) Franco regulates M1/M2 polarization of macrophages and promotes hair regeneration. (PubMed, J Ethnopharmacol) - "The inhibition of macrophage-mediated inflammatory infiltration by CE showed a strong germinal effect, providing new insights into CE's effect on AA."

Journal • Alopecia • Immunology • Inflammation • CD4 • CD8 • IFNG • IL4 • TNFA